Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01386580 · ClinicalTrials.gov registry record · Phase 1
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
A Phase 1 study of Breast Cancer and Lung Cancer, sponsored by BBB-Therapeutics B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 10
- Study locations
NCT01386580 is a Phase 1 study of Breast Cancer and Lung Cancer that has completed, run by BBB-Therapeutics B.V.. The registered enrollment target is 84 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 4 states.
The verdict
NCT01386580, a Phase 1 study of Breast Cancer and Lung Cancer, has completed, sponsored by BBB-Therapeutics B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of 2B3-101 both as single agent and in combination with trastuzumab. Furthermore, the study will explore the preliminary antitumor activity of 2B3-101 as single agent in patients with with solid tumors and brain metastases or recurrent malignant glioma as well as in patients with various forms of breast cancer with and in combination with trastuzumab in HER2+ breast cancer patients with brain metastases.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG 2B3-101
- DRUG 2B3-101 60 mg/m2 every 4 weeks
- DRUG 2B3-101 50 mg/m2 every 3 weeks
Study Locations (10)
Other
- Universitair Ziekenhuis Antwerpen - Antwerp
- Jules Bordet Institute - Brussels
- Antoni van Leeuwenhoek Ziekenhuis - Amsterdam
- Vrije Universiteit medisch centrum (Vumc) - Amsterdam
- Leids Universitair Medisch Centrum (LUMC) - Leiden
- Maastricht Universitair Medisch Centrum - Maastricht
- Erasmus MC - Rotterdam
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
Paris Cedex 05
- Institut Curie - Paris
Val de Marne
- Institut Gustave Roussy - Villejuif
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01386580
The ClinicalTrials.gov registry entry for NCT01386580 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is BBB-Therapeutics B.V., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Trastuzumab is the first listed.
NCT01386580 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Other, North Carolina, Paris Cedex 05.
Frequently Asked Questions
What is clinical trial NCT01386580 about?
NCT01386580 is a clinical study titled "An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.". The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of 2B3-101 both as single agent and in combination with trastuzumab. Furthermore, the study will explore the preliminary antitumor activity of 2B3-101 as single agent in patients with with solid tumors and ...
What is the current status of trial NCT01386580?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2011-07. Estimated completion is 2014-12.
What conditions does trial NCT01386580 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Melanoma, Brain Metastases, Malignant Glioma.
What interventions are being tested in trial NCT01386580?
The interventions under investigation include: Trastuzumab (DRUG), 2B3-101 (DRUG), 2B3-101 60 mg/m2 every 4 weeks (DRUG), 2B3-101 50 mg/m2 every 3 weeks (DRUG).
Who is sponsoring clinical trial NCT01386580?
This trial is sponsored by BBB-Therapeutics B.V., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01386580 being conducted?
This trial has 10 study locations across North Carolina, Paris Cedex 05, Val de Marne. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.